In 1968, Richard T. Silver, MD, a prominent hematologist-oncologist, founded the Cancer Research & Treatment Fund (CR&T) with the belief that investing in blood cancer research would lead to important breakthroughs, as well as a better understanding of the biology and treatment of all forms of cancer. While the focus of the organization is the myeloproliferative neoplasms (MPNs), over the course of its 53-year history, CR&T has awarded more than $17 million in grants to research that has contributed to major advances in the fight against cancer.